Literature DB >> 16897249

Comparison between neurotropin and mepivacaine for stellate ganglion injection.

Tomoki Nishiyama1, Takashi Matsukawa, Koichi Yamashita.   

Abstract

Neurotropin, a nonproteinaceous extract from the inflamed skin of rabbits inoculated with vaccinia virus, is reported to decrease pain effectively when used for stellate ganglion (SG) injection. We compared the effects of neurotropin SG injection with those of mepivacaine on pain relief, as well as comparing the side effects. One hundred and eighty-eight SG injections in 15 patients (5 with postherpetic neuralgia and 10 with sudden deafness) were performed either with 1% mepivacaine 6 ml or with neurotropin 3 ml combined with saline 3 ml in turn. Fifteen min before and after the injection, the pain score, according to a visual analog scale (VAS; only in patients with postherpetic neuralgia); blood pressure; and heart rate were checked, and the number of procedures with Horner's sign was determined. VAS scores decreased significantly with both injections. Horner's sign was observed on the block side in all procedures with the mepivacaine injection, but it was seen in only 48 procedures with the neurotropin injection. Blood pressure and heart rate did not change. In conclusion, the SG injection of neurotropin decreased the VAS score in postherpetic neuralgia to the same extent as mepivacaine. The incidence of Horner's sign was significantly lower with neurotropin than with mepivacaine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16897249     DOI: 10.1007/s00540-006-0399-4

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.931


  5 in total

1.  Mechanism of the analgesic effect of neurotropin.

Authors:  T Hata; T Kita; E Itoh; R Oyama; A Kawabata
Journal:  Jpn J Pharmacol       Date:  1988-10

2.  [Central activity, antihypertensive action and antiulcerogenic effects of neurotropin].

Authors:  T Hata; T Kita; R Yoneda
Journal:  Nihon Yakurigaku Zasshi       Date:  1976-10

3.  Antinociceptive effects of neurotropin in a rat model of painful peripheral mononeuropathy.

Authors:  K Toda; H Muneshige; Y Ikuta
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

4.  Reflex sympathetic dystrophy in childhood: a case report.

Authors:  T Okada; M Maeda; T Takechi; T Tomoda; H Wakiguchi; T Kurashige
Journal:  Acta Paediatr Jpn       Date:  1997-12

5.  Neurotropin induces antinociceptive effect by enhancing descending pain inhibitory systems involving 5-HT3 and noradrenergic alpha2 receptors in spinal dorsal horn.

Authors:  M Kawamura; H Ohara; K Go; Y Koga; K Ienaga
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

  5 in total
  4 in total

Review 1.  Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks.

Authors:  Angela Mailis; Paul Taenzer
Journal:  Pain Res Manag       Date:  2012 May-Jun       Impact factor: 3.037

2.  Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study.

Authors:  Tomoko Nakai; Daisuke Sakai; Yoshihiko Nakamura; Natsumi Horikita; Erika Matsushita; Mitsuru Naiki; Masahiko Watanabe
Journal:  BMC Med Genomics       Date:  2021-03-11       Impact factor: 3.063

3.  A Randomized Comparison between 4, 6 and 8 mL of Local Anesthetic for Ultrasound-Guided Stellate Ganglion Block.

Authors:  Yongjae Yoo; Chang-Soon Lee; Yong-Chul Kim; Jee Youn Moon; Roderick J Finlayson
Journal:  J Clin Med       Date:  2019-08-27       Impact factor: 4.241

4.  Upregulation of glycosaminoglycan synthesis by Neurotropin in nucleus pulposus cells via stimulation of chondroitin sulfate N-acetylgalactosaminyltransferase 1: A new approach to attenuation of intervertebral disc degeneration.

Authors:  Daisuke Sakai; Tomoko Nakai; Shunsuke Hiraishi; Yoshihiko Nakamura; Kiyoshi Ando; Mitsuru Naiki; Masahiko Watanabe
Journal:  PLoS One       Date:  2018-08-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.